Evaluation of the efficacy of desmopressin in the treatment of disorders of primary haemostasis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039373

Enrollment

100

Registered

2026-02-19

Start date

2025-05-13

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N19

Interventions

Group 1: Suspected platelet function disorder with an indication for the administration of desmopressin to improve primary haemostasis Before desmopressin administration: In vitro bleeding time (curre

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient age > 16 years Congenital or acquired disorder of primary haemostasis with an indication for desmopressin administration (e.g., in the context of a desmopressin test or prior to a renal procedure)

Exclusion criteria

Exclusion criteria: no suspicion of alteration of primary haemostastasis

Design outcomes

Primary

Measure	Time frame
In vitro bleeding time vWF antigen/activity Blood group (if applicable) Thrombin generation (PRP, PPP) Thromboelastography (EXTEM test, TPA test) Plasma-based global coagulation parameters and complete blood count	—

Secondary

Measure	Time frame
-questionnaire (ISTH) -anamnestic information to bleeding and thrombembolic events -current bleeding tendencies	—

Countries

Germany

Contacts

Public ContactKarina Althaus

Institut für klinische und experimentelle Transfusionsmedizin

Karina.Althaus@med.uni-tuebingen.de+49070712981605

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026